JP2024512978A - 免疫細胞組成物を生成するための方法 - Google Patents

免疫細胞組成物を生成するための方法 Download PDF

Info

Publication number
JP2024512978A
JP2024512978A JP2023559686A JP2023559686A JP2024512978A JP 2024512978 A JP2024512978 A JP 2024512978A JP 2023559686 A JP2023559686 A JP 2023559686A JP 2023559686 A JP2023559686 A JP 2023559686A JP 2024512978 A JP2024512978 A JP 2024512978A
Authority
JP
Japan
Prior art keywords
composition
approximately
immune cell
cells
cell population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023559686A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024512978A5 (enExample
Inventor
ジン リー、ヒー
ジン リー、キュ
セオン パク、ヒェ
ヤブ ゴン、ギュン
リュル リム、チャエ
アエ キム、ヨウン
イル チョイ、ジ
Original Assignee
ネオジェント コーポレーション
ザ アサン ファンデーション
ユニヴァーシティ オブ ウルサン ファンデーション フォー インダストリー コオペレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネオジェント コーポレーション, ザ アサン ファンデーション, ユニヴァーシティ オブ ウルサン ファンデーション フォー インダストリー コオペレーション filed Critical ネオジェント コーポレーション
Publication of JP2024512978A publication Critical patent/JP2024512978A/ja
Publication of JP2024512978A5 publication Critical patent/JP2024512978A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/30—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cancer cells, e.g. reversion of tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Clinical Laboratory Science (AREA)
  • Sustainable Development (AREA)
JP2023559686A 2021-03-30 2022-03-30 免疫細胞組成物を生成するための方法 Pending JP2024512978A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20210040926 2021-03-30
KR10-2021-0040926 2021-03-30
PCT/KR2022/004509 WO2022211491A1 (ko) 2021-03-30 2022-03-30 면역세포 조성물을 생산하는 방법

Publications (2)

Publication Number Publication Date
JP2024512978A true JP2024512978A (ja) 2024-03-21
JP2024512978A5 JP2024512978A5 (enExample) 2025-04-03

Family

ID=83459472

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023559686A Pending JP2024512978A (ja) 2021-03-30 2022-03-30 免疫細胞組成物を生成するための方法

Country Status (5)

Country Link
US (1) US20240181053A1 (enExample)
EP (1) EP4317423B1 (enExample)
JP (1) JP2024512978A (enExample)
KR (2) KR102666931B1 (enExample)
WO (1) WO2022211491A1 (enExample)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170152478A1 (en) * 2011-03-22 2017-06-01 The Usa, As Represented By The Secretary, Department Of Health And Human Service Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
JP2020515257A (ja) * 2017-03-29 2020-05-28 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用方法
KR20200092155A (ko) * 2019-01-24 2020-08-03 울산대학교 산학협력단 종양침윤림프구를 유효성분으로 포함하는 삼중음성 유방암 예방 또는 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019136459A1 (en) * 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
CA3094957A1 (en) * 2018-03-29 2019-10-03 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2019210131A1 (en) * 2018-04-27 2019-10-31 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2019217753A1 (en) * 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2020096927A1 (en) * 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
WO2020232029A1 (en) * 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
CN110938594A (zh) * 2019-09-12 2020-03-31 夏建川 一种功能增强型til细胞的培养方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170152478A1 (en) * 2011-03-22 2017-06-01 The Usa, As Represented By The Secretary, Department Of Health And Human Service Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
JP2020515257A (ja) * 2017-03-29 2020-05-28 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用方法
KR20200092155A (ko) * 2019-01-24 2020-08-03 울산대학교 산학협력단 종양침윤림프구를 유효성분으로 포함하는 삼중음성 유방암 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
US20240181053A1 (en) 2024-06-06
EP4317423B1 (en) 2026-05-06
KR102666931B1 (ko) 2024-05-20
KR20240078405A (ko) 2024-06-03
EP4317423A4 (en) 2025-04-09
KR20220136919A (ko) 2022-10-11
EP4317423A1 (en) 2024-02-07
WO2022211491A1 (ko) 2022-10-06

Similar Documents

Publication Publication Date Title
KR20170067751A (ko) 저산소 및 정상산소 교대 조건에서 골수 침윤성 림프구의 활성화
US12110506B2 (en) Method for culturing tumor infiltrating lymphocytes
KR101521484B1 (ko) 메모리 t세포를 주성분으로 하는 림프구 세포군의 제조 방법
AU2023221021B2 (en) Compositions and methods for antigen-specific t cell expansion
JP2022121446A (ja) 幹細胞移植のための方法および組成物
Wickström et al. Expansion of tumor-infiltrating lymphocytes from melanoma tumors
CN113454209A (zh) 通用型双阴性t细胞的制备和治疗用途
CA3150732A1 (en) Methods of determining the suitability of cultured thymus tissue for implantation into humans and associated methods of use
US20250186505A1 (en) Methods of Determining the Suitability of Cultured Thymus Tissue for Implantation Into Humans and Associated Methods of Use
JP2024512978A (ja) 免疫細胞組成物を生成するための方法
CN120036303A (zh) 一种细胞冻存液及其应用
CN103585179A (zh) 一种药物组合物及其在制备治疗骨髓造血功能障碍疾病的药物中的应用
JPH08205860A (ja) 造血細胞の膨大化および移植方法
CN114908050A (zh) 肿瘤浸润淋巴细胞的制备方法及其用途
US12440565B1 (en) Dendritic cell preparation and preparation method thereof
WO2024131741A1 (zh) 一种细胞冻存方法及其用途
US20240400992A1 (en) Compositions and methods for antigen-specific t cell expansion
WO2024230569A1 (zh) 肿瘤浸润淋巴细胞在疾病治疗中的用途
JP2025146940A (ja) 拡大した幹細胞生成物を使用して、血液悪性腫瘍を有する患者の処置転帰を改善するための組成物および方法
WO2026067822A1 (zh) 一种扩增的肿瘤反应性t细胞组合物
WO2023125772A1 (zh) 一种修饰的肿瘤浸润淋巴细胞及其用途
WO2023138598A1 (zh) 肿瘤浸润淋巴细胞在疾病治疗中的用途
TW202218671A (zh) 測定經培養胸腺組織植入人體內之適用性之方法及相關使用方法
HK40063163B (zh) 确定培养的胸腺组织用於植入至人中的适合性的方法及其相关使用方法
McKAY A Cryopreservation Protocol to Retain T Cell Function and Viability for Use in Donor Leukocyte Infusion

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250326

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260303